American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Rosen
    Rosen
  4. Solit
    Solit
  5. Traina
    Traina
  6. Fornier
    Fornier
  7. Modi
    Modi
  8. Seidman
    Seidman
  9. Reidy
    Reidy
  10. Saltz
    Saltz

Groups

  1. Breast Medicine Service (21)
  2. Department of Medicine (21)
  3. Solid Tumor Oncology Division (21)
  4. Survivorship Research (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  6. GSK Faculty (5)
  7. Genitourinary Oncology Service (5)
  8. Epidemiology and Biostatistics (4)
  9. Human Oncology and Pathogenesis Program (4)
  10. Molecular Pharmacology and Chemistry Program Faculty (4)
Search Within
  1. "2007"
  2. "Breast Medicine Service"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (10)
Groups
  1. Breast Medicine Service (21)
  2. Department of Medicine (21)
  3. Solid Tumor Oncology Division (21)
  4. Survivorship Research (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  6. GSK Faculty (5)

More Groups

People
  1. Clifford Hudis (11)
  2. Larry Norton (8)
  3. David Solit (4)
  4. Neal Rosen (4)
  5. Tiffany Traina (4)
  6. Andrew Seidman (3)

More People

Years
  1. 2007 (21)
Publications
  1. Journal of Clinical Oncology (21)

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model
    Meeting Abstract

    Traina, T. A.; Higgins, B.; Theodoulou, M.; Dugan, U.; Kolinsky, K.; Zhang, Y.; Heimbrook, D.; Packman, K.; Hudis, C.; Norton, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Theodoulou, M.; Traina, T. A.; Dugan, U.; Lake, D.; Fornier, M.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • BRAF mutation predicts MEK-dependence in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pratilas, C. A.; Halilovic, E.; Sawai, A.; Grbovic-Huezo, O.; Rosen, N.; Solit, D. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Impact of risk-reducing oophorectomy on quality of life in women at risk for ovarian cancer
    Meeting Abstract

    McArthur, H. L.; Hensley, M.; Brown, C. L.; Chi, D. S.; Offit, K.; Hurley, K.; Li, Y.; Gemignani, M. L.; Robson, M. E.; Barakat, R. R.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)
    Meeting Abstract

    Miller, K.; Rosen, L. S.; Modi, S.; Schneider, B.; Roy, J.; Chap, L.; Paulsen, M.; Kersey, K.; Hannah, A.; Hudis, C.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
    Meeting Abstract

    Kaufman, P. A.; Broadwater, G.; Lezon-Geyda, K.; Dressler, L. G.; Berry, D.; Friedman, P.; Winer, E. P.; Hudis, C.; Ellis, M. J.; Seidman, A. D.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Meeting Abstract

    Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save